Metformin and ageing: improving ageing outcomes beyond glycaemic control

Diabetologia

Volumn 60, Issue 9, 2017, Pages 1630-1638

  Valencia, Willy Marcos ^a,b   Palacio, Ana ^a,b   Tamariz, Leonardo ^a,b   Florez, Hermes ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Ageing; Mechanisms of ageing; Metformin; Older adults; Review

Indexed keywords

METFORMIN; REACTIVE OXYGEN METABOLITE; ANTIDIABETIC AGENT;

AGING; ALZHEIMER DISEASE; ANGIOGENESIS; CARDIOVASCULAR RISK; CELL METABOLISM; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DISEASE ASSOCIATION; DNA DAMAGE; GENETIC DAMAGE; GLYCEMIC CONTROL; HEART MUSCLE REVASCULARIZATION; HUMAN; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION; ANIMAL; DRUG EFFECT; GLUCOSE BLOOD LEVEL; PHYSIOLOGY;

AGING; ANIMALS; BLOOD GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 85026748623     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4349-5     Document Type: Review

References (69)

1. World Health Organization (2015) Ageing and health. Fact sheet N404. Available from www.who.int/mediacentre/factsheets/fs404/en/. Accessed 7 Mar 2017
2. Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and nutrition examination survey. JAMA 287:356–359
3. Bonora E, Kiechl S, Willeit J et al (2007) Insulin resistance as estimated by homeostatis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care 30:318–324
4. Djioque S, Nwabo Kamdje AH, Vecchio L et al (2013) Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer 20:R1–R17
5. Stuart MJ, Baune BT (2012) Depression and type 2 diabetes: inflammatory mechanisms of a psychoneuroendocrine comorbidity. Neurosci Biobehav Rev 36:658–676
6. De Felice FG, Ferreira ST (2014) Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63:2262–2272
7. Espinoza SE, Jung I, Hazuda H (2012) Frailty transitions in the San Antonio longitudinal study of aging. J Am Geriatr Soc 60:652–660
8. Crandall J et al (2006) (DPP research group). The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol 61:1075–1081
9. Knowler W et al (2014) (DPP research group). HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention Program: a randomized clinical trial. Diabetes Care 38:51–58
10. Losordo DW, Henry TD (2016) New definition of aging?: measuring regenerative capacity in patients. Circ Res 119:774–775
11. Barzilai N, Huffman DM, Muzumdar RH, Bartke A (2012) The critical role of metabolic pathways in aging. Diabetes 61:1315–1322
12. Goldberg EL, Dixit VD (2015) Drivers of age-related inflammation and strategies for healthspan extension. Immunol Rev 265:63–74
13. Harris RA, Tindale L, Cumming RC (2014) Age-dependent metabolic dysregulation in cancer and Alzheimer’s disease. Biogerontology 15:559–577
14. Fedarko N, McNabney MK (2016) Biology. In: Medina-Walpole A, Pacala JT (eds) Geriatrics review syllabus. 9th edn. American Geriatrics Society. Available at https://geriatricscareonline.org/ProductAbstract/geriatrics-review-syllabus9th-edition/B023/. Accessed 16 Mar 2017
15. Hoeijmakers JHJ (2009) DNA damage, aging, and cancer. N Engl J Med 361:1475–1485
16. Tamariz L, Hare JM (2015) Xanthine oxidase inhibitors in heart failure: where do we go from here? Circulation 131:1741–1744
17. Carney JM, Starke-Reed PE, Oliver CN et al (1991) Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-alpha-phenylnitrone. Proc Natl Acad Sci US A 88:3633–3636
18. Milholland B, Suh Y, Vijg J (2017) Mutation and catastrophe in the aging genome. Exp Gerontol 94:34–40
19. Inouye SK, Studenski S, Tinetti ME, Kuchel GA (2007) Geriatric syndromes: clinical, research and policy implications of a core geriatric concept. J Am Geriatr Soc 55:780–791
20. Valencia WM, Florez H (2017) Endocrinology and metabolism. In: Burton J, Lee A, Potter J (eds) Geriatrics for specialists. Springer, Switzerland, pp 269–282
21. Madiraju AK, Erion DM, Rahimi Y et al (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510:542–546
22. Tamariz L, Hare JM (2010) Inflammatory cytokines in heart failure: roles in aetiology and utility as biomarkers. Eur Heart J 31:768–770
23. Saisho Y (2015) Metformin and inflammation: its potential beyond glucose-lowering effect. Endocr Metab Immune Disord Drug Targets 15:196–205
24. Mancini SJ, White AD, Bijland S et al (2017) Activation of AMP-activated protein kinase rapidly suppresses multiple pro-inflammatory pathways in adipocytes including IL-1 receptor-associated kinase-4 phosphorylation. Mol Cell Endocrinol 440:44–56
25. Moiseeva O, Deschenes-Simard X, St-Germain E et al (2013) Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-kappa B activation. Aging Cell 12:489–498
26. Batandier C, Guigas B, Detaille D et al (2006) The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. J Bioenerg Biomembr 38:33–42
27. Algire C, Moiseeva O, Deschenes-Simard X et al (2012) Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res 5:536–543
28. Halicka HD, Zhao H, Li J et al (2012) Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage-signaling. Aging 4:952–965
29. Jadhav KS, Dungan CM, Williamson DL (2013) Metformin limits ceramide-induced senescence in C2C12 myoblasts. Mech Ageing Dev 134:548–559
30. Anisimov VN, Berstein LM, Egormin PA et al (2008) Metformin slows down aging and extends lifespan of female SHR mice. Cell Cycle 7:2769–2773
31. Cabreiro F, Au C, Leung KY et al (2013) Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 153:228–239
32. De Haes W, Frooninckx L, Van Assche R et al (2014) Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2. Proc Natl Acad Sci U S A 111:E2501–E2509
33. Takahashi N, Shibata R, Ouchi N, Sugimoto M, Murohara T, Komori K (2015) Metformin stimulates ischemia-induced revascularization through an eNOS dependent pathway in the ischemic hindlimb mice model. J Vasc Surg 61:489–496
34. Meng X, Chu G, Yang Z et al (2016) Metformin protects neurons against oxygen-glucose deprivation/reoxygenation -induced injury by down-regulating MAD2B. Cell Physiol Biochem 40:477–485
35. El-Mir MY, Detaille D, R-Villanueva G et al (2008) Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci 34:77–87
36. Kumar A, Al-Sammarraie N, DiPette DJ, Singh US (2014) Metformin impairs rho GTPase signaling to induce apoptosis in neuroblastoma cells and inhibits growth of tumors in the xenograft mouse model of neuroblastoma. Oncotarget 5:11709–11722
37. Gupta A, Bisht B, Dey CS (2011) Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes. Neuropharmacology 60:910–920
38. Johnson JA, Simpson SH, Toth EL, Majumdar SR (2005) Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 22:497–502
39. Wang CP, Lorenzo C, Habib SL, Espinoza SE (2017) Differential effects of metformin on age related comorbidities in older men with type 2 diabetes. J Diabetes Complicat 31:679–686
40. Petrie JR, Chatuverdi N, Ford I et al (2017) Metformin in adults with type 1 diabetes: design and methods of REducing with MetfOrmin vascular adverse lesions (REMOVAL): an international multicentre trial. Diabetes Obes Metab 19:509–516
41. Preiss D, Lloyd SM, Ford I et al (2014) Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol 2:116–124
42. Goldberg RB, Mather K (2012) Targeting the consequences of the metabolic syndrome in the diabetes prevention Program. Arterioscler Thromb Vasc Biol 32:2077–2090
43. Morgan CL, Jenkins-Jones S, Evans M, Barnett AH, Poole CD, Currie CJ (2012) Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. Diabetes Obes Metab 14:424–432
44. Haffner S, Temprosa M, Crandall J et al (2005) Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 54:1566–1572
45. Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM (2005) Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 258:250–256
46. de Aguiar LG, Bahia LR, Villela N et al (2006) Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 29:1083–1089
47. Jadhav S, Ferrell W, Greer IA, Petrie JR, Cobbe SM, Sattar N (2006) Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 48:956–963
48. Whittington HJ, Hall AR, McLaughlin CP, Hausenloy DJ, Yellon DM, Mocanu MM (2013) Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther 27:5–16
49. UKPDS Study Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865
50. Kooy A, de Jager J, Lehert P et al (2009) Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 169:616–625
51. Guo M, Mi J, Jiang QM et al (2014) Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharmacol Physiol 41:650–656
52. Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B (2014) Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis 41:61–68
53. Hsu CC, Wahlqvist ML, Lee MS, Tsai HN (2011) Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis 24:485–493
54. Cheng C, Lin CH, Tsai YW, Tsai CJ, Chou PH, Lan TH (2014) Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis. J Gerontol A Biol Sci Med Sci 69:1299–1305
55. Luchsinger JA, Perez T, Chang H et al (2016) Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial. J Alzheimers Dis 51:501–514
56. Moreira PI (2014) Metformin in the diabetic brain: friend or foe? Ann Transl Med 2:54
57. Barini E, Antico O, Zhao Y et al (2016) Metformin promotes tau aggregation and exacerbates abnormal behaviour in a mouse model of taupathy. Mol Neurodegener 11:16
58. Thangthaeng N, Rutledge M, Wong JM, Vann PH, Forster MJ, Sumien N (2017) Metformin impairs spatial memory and visual acuity in old male mice. Aging and Disease 8:17–30
59. Luchsinger JA, Ma Y, Christophi CA et al (2017) Metformin, lifestyle intervention, and cognition in the Diabetes Prevention Program Outcomes Study. Diabetes Care 40:958–965
60. Kirkman SM, Briscoe VJ, Clark N et al (2012) Diabetes in older adults. Diabetes Care 35:2650–2664
61. Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEJM 346:393–403
62. US Food and Drug Administration. Metformin containing drugs: drug safety communication – revised warnings for certain patients with reduced kidney function. Available from https://www.fda.gov/Safety/MedWatch/safetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494829.htm?source5govdelivery&utm_medium5email&utm_source5govdelivery. Accessed 24 May 2017
63. European Medicines Agency. Metformin and metformin-containing medicines. Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function. Available from www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Metformin_and_metformin-containing_medicines/human_referral_000397.jsp&mid=WC0b01ac05805c516f. Accessed 24 May 2017
64. Misban RI (2004) The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care 27:1791–1793
65. DeFronzo R, Fleming GA, Chen K, Bicsak TA (2016) Metformin associated lactic acidosis: current perspectives on causes and risk. Metabolism 65:20–29
66. Valencia WM, Florez H (2014) Pharmacological treatment of diabetes in older people. Diabetes Obes Metab 16:1192–1203
67. Valencia WM, Stoutenberg M, Florez H (2014) Weight loss and physical activity for disease prevention in obese older adults: an important role for lifestyle management. Curr Diab Rep 14:539
68. Newman JC, Milman S, Hashmi SK et al (2016) Strategies and challenges in clinical trials targeting human aging. J Gerontol A Biol Sci Med Sci 74:1424–1434
69. The ePREDICE Consortium (2016) Early Prevention of Diabetes Complications in Europe. Available from www.epredice.eu/en/the-project. Accessed 22 Feb 2017